Alimera Sciences Reports Record Fourth Quarter and 2018 Results
Fourth Quarter 2018 Highlights
Fourth quarter 2018 consolidated net revenue up 66%
International segment revenue increased 138% over the prior year period
Net Loss of $1.2 million vs. Net Loss of $7.2 million during 4Q17
Positive Adjusted EBITDA of $2.4 million vs. Adjusted EBITDA loss of $3.8 million during 4Q17
Year-End 2018 Highlights
Consolidated net revenue up 31% in 2018 vs. 2017
U.S. net revenue increased 24%; International segment increased 49%
ATLANTA, February 18, 2018 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced financial results for the three and twelve month periods ended December 31, 2018. Alimera will host a conference call on February 19, 2019, at 9:00 a.m. ET to discuss these results.
“During 2018, we achieved substantial growth resulting in record revenues in the U.S. and our international segment. We also achieved our goal of positive adjusted EBITDA in Q4 2018,” said Rick Eiswirth, Alimera’s President and Chief Executive Officer. “We believe we have an opportunity for significant revenue growth in 2019 and intend to further enhance Alimera’s value.”
Fourth Quarter and Full Year 2018 Financial Results
Consolidated Net Revenue
Consolidated net revenue increased 66% to approximately $15.1 million for the three months ended December 31, 2018, compared to approximately $9.1 million for the three months ended December 31, 2017.
For 2018, consolidated net revenue increased 31% to approximately $47.0 million, compared to approximately $35.9 million in 2017.
U.S. Net Revenue
U.S. net revenue grew 37% to approximately $8.9 million for three months ended December 31, 2018, compared to U.S. net revenue of approximately $6.5 million for the three months ended December 31, 2017. The increase in U.S. net revenue was attributable to increased demand and purchases from Alimera’s distributors. End user demand, which represents units purchased by physicians and pharmacies from Alimera’s distributors, increased 14% to 1,019 units compared to 896 units during 2017.
The following information was filed by Alimera Sciences Inc (ALIM) on Tuesday, February 19, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Alimera Sciences Inc's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed, and by Alimera Sciences Inc.
Ticker: ALIM CIK: 1267602 Form Type:10-K Annual Report Accession Number: 0001267602-19-000043 Submitted to the SEC: Mon Feb 25 2019 4:58:39 PM EST Accepted by the SEC: Mon Feb 25 2019 Period: Monday, December 31, 2018 Industry: Pharmaceutical Preparations